Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novo Nordisk is paying Valo Health $60 million upfront and up to $2.76 billion in milestones to collaborate on AI-discovered cardiometabolic drug targets,…
Novo Nordisk announced a discovery and development collaboration with Boston-based Valo Health, agreeing to pay up to $2.76 billion plus undisclosed upfront…
Novo Nordisk IR confirmation of the Jan 8, 2025 expanded Valo Health collaboration: up to 20 programs across obesity, type 2 diabetes and cardiovascular…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Novo Nordisk and Valo Health entered a discovery/development collaboration on Sept 25, 2023, leveraging Valo's Opal Computational Platform and proprietary human dataset to identify novel cardiovascular/cardiometabolic targets. Original terms: $60M in upfront/near-term payments and eligibility for up to $2.7B across up to 11 programs in milestones, plus R&D funding and royalties. On Jan 8, 2025 the partners EXPANDED the alliance: scope broadened to obesity and type 2 diabetes in addition to cardiovascular disease, the program count rose to up to 20 (9 new programs), and Valo became eligible for ~$4.6B in milestones with up to $190M in near-term payments (upfront plus an equity investment by Novo Nordisk and a potential near-term milestone), again with R&D funding and tiered royalties. Novo's CSO Marcus Schindler cited first-year progress and the addition of several novel cardiometabolic targets as the rationale for the expansion. Note: Valo's separate wholly-owned ROCK inhibitor OPL-0401 failed its Phase 2 diabetic-retinopathy endpoint and was suspended; that asset is outside the Novo collaboration and does not bear on this deal's programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Valo Health, Inc. (this deal) | 2023 | $4.8B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2023 deals · Novo Nordisk A/S deals · Cardiovascular deals